Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12239696-B2
Publication Date
2025-03-04
Expiration Date
Abstract
Provided herein are chimeric recombinant polypeptides (chimeritopes) for use in vaccines against Anaplasmosis, in assays for diagnosing Anaplasmosis and in assays for measuring antibody titers induced by vaccination. The chimeritopes comprise, for example, antigenic segments of three Anaplasma proteins (OmpA, AipA and Asp14) and a non-antigenic segment of a Borrelia Osp protein (e.g. OspC) that is 10 amino acids in length, proline rich and random coil in conformation. Compositions comprising the chimeritopes, optionally in combination with additional Anaplasma proteins of interest, are also provided, as are methods of using the compositions as vaccines and diagnostic tools.
Core Innovation
The document describes recombinant Anaplasma chimeritopes comprising repeated invasion epitopes from OmpA, AipA, and Asp14, with an optional Borrelia OspC-derived C-terminal cap. These chimeritopes are administered as pharmaceutical compositions of recombinant chimeric polypeptides to elicit an immune response to Anaplasma. Specific variants elicit antibodies that inhibit Anaplasma binding, invasion, and infection of mammalian cells.
The disclosure demonstrates antibody responses and enhanced in-vitro blocking when antibodies to AP4 are combined with antibodies to P130 and APH_1235. Assays indicate antibody-associated reductions in Anaplasma-infected cells and ApV counts, confirming immunogenicity and inhibition of cellular binding. Because the background section is absent from the provided text, the problem being solved is not explicitly described in patent.
Claims Coverage
The claim coverage encompasses two inventive features across two independent claims relating to methods of administering a recombinant chimeric polypeptide.
Eliciting an immune response to Anaplasma
Administering a pharmaceutical composition comprising a recombinant, chimeric polypeptide with an amino acid sequence selected from SEQ ID NOs: 8–23, in an amount sufficient to elicit an immune response in the subject.
Blocking or attenuating Anaplasma binding to mammalian cells
Administering a pharmaceutical composition comprising a recombinant, chimeric polypeptide with amino acid sequence SEQ ID NO: 13 or SEQ ID NO: 15, in an amount sufficient to elicit antibodies that block or attenuate Anaplasma binding to mammalian cells in the subject.
The two inventive features address eliciting an immune response and blocking or attenuating Anaplasma binding to mammalian cells using designated recombinant chimeric polypeptides.
Stated Advantages
Antibodies elicited by AP3 and AP4 variants inhibit Anaplasma binding, invasion, and infection of mammalian cells.
Combining AP4 antibodies with antibodies to P130 and APH_1235 enhances in-vitro blocking.
Documented Applications
Vaccination using recombinant chimeritopes to elicit an immune response to Anaplasma in a subject.
Blocking or attenuating Anaplasma binding to mammalian cells in a subject through antibody elicitation.
Diagnostic assays.
Measurement of vaccine-induced antibody titers.
Interested in licensing this patent?